Drug intelligence / Profile preview

MSB-6005

Development stage: Unknown
Lead developer: MatriSys Bioscience
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

MSB-6005 is an investigational live biotherapeutic product (LBP) developed by MatriSys Biosciences for the treatment of Netherton syndrome and rosacea. The therapy is based on the company's proprietary platform that utilizes beneficial commensal skin bacteria to restore the natural balance of the skin microbiome and displace pathogenic organisms. In patients with Netherton syndrome—a rare and severe genetic skin disorder characterized by a defective skin barrier and chronic inflammation—MSB-6005 aims to address microbial dysbiosis and reduce the risk of secondary infections, particularly those caused by *Staphylococcus aureus*. By reintroducing healthy commensals, the treatment seeks to improve skin barrier function and mitigate inflammatory symptoms. MSB-6005 is currently in Phase 1 clinical development for Netherton syndrome and in preclinical stages for the treatment of rosacea.

Targets

Commensal skin bacteria

Beyond the preview

Go deeper on MSB-6005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSB-6005.

Explore the full profile